Independent report
Third primary COVID-19 vaccine dose for people who are immunosuppressed: JCVI advice
Statement from the Joint Committee on Vaccination and Immunisation (JCVI) on the benefits of a third primary COVID-19 vaccine dose in individuals aged 12 years and over with severe immunosuppression.
Documents
Details
This statement sets out advice from the JCVI on the benefits of a third primary COVID-19 vaccine dose in individuals aged 12 years and over with severe immunosuppression around the time of their first or second vaccine doses.
See also:
- 闯颁痴滨鈥檚 first statement on COVID-19 vaccination of children and young people aged 12 to 17 years, published in July 2021
- 闯颁痴滨鈥檚 updated statement on COVID-19 vaccination of children and young people aged 12 to 17 years published in August 2021
Updates to this page
Published 1 September 2021